If the interferon response is late and weak, does supplying it early help?
If the defining feature of SARS-CoV-2 infection is a muted interferon response alongside vigorous chemokine output, the obvious therapeutic inference is to supply the missing arm. Several independent lines of evidence made that inference attractive by late 2020, including reports of autoantibodies against type I interferon and inborn errors affecting TLR3 and IRF7 among patients with critical disease. Against that, systemic interferon had performed poorly in trials, with the SOLIDARITY trial showing no mortality benefit, and systemic administration carries tolerability costs.
Testing the idea required something clinical sampling cannot provide, namely the full course of infection across tissues in a host where an unmodified clinical isolate causes progressive lower respiratory disease. It also required deciding what the interferon seen away from the airway actually means. An antiviral transcriptional state in brain or kidney could report local infection, or it could report a signal arriving from somewhere else, and those two readings imply different interventions.
Both publications carry the contribution character lab-led.
Hoagland 2021 built the descriptive and interventional arms in the same model. Golden hamsters were chosen because they are naturally permissive without host genetic modification. Because Ifnb1 was unannotated in the hamster genome, the authors performed a de novo assembly, cloned a candidate transcript and showed it induces interferon-stimulated genes in hamster but not human cells, which is what made interferon biology readable in this species. Against a matched influenza A virus comparison at equivalent viral load, SARS-CoV-2 drove higher inflammatory and neutrophil-associated transcripts. Ten plaque forming units sufficed to seed the lower respiratory tract, and raising the inoculum a thousandfold did not increase replication. Inflammation moved from upper to lower airway over several days, and olfactory bulb, brain and small intestine showed strong antiviral transcription despite viral reads orders of magnitude below respiratory levels. Intranasal universal interferon alpha A/D, given before challenge or starting one day after, reduced infectious virus and proinflammatory transcripts, shifted the infiltrate away from neutrophils, and prevented transmission in three of five contact-exposed animals. An intranasal double-stranded RNA mimetic gave comparable antiviral activity.
Carrau 2023 then resolved the question Hoagland 2021 had left open about the distal response. Hoagland 2021 had proposed, explicitly as speculation, that disseminated viral RNA acts as a pathogen-associated molecular pattern away from the airway. Carrau 2023 tested the alternative and found for it. Nine organs showed an interferon signature three days after intranasal challenge while infectious virus was largely confined to lung and olfactory bulb. Whole blood carried an interferon-stimulated gene signature with no interferon transcripts of its own, and a bioassay on hamster fibroblasts detected roughly sixty units per millilitre of circulating interferon at one day. Three manipulations then pointed the same way. Dexamethasone delayed airway interferon-stimulated gene induction without changing early lung titres and permitted infectious virus in liver, spleen, olfactory bulb and gastrointestinal tract, with low level viremia detectable only after amplification. Intravenous delivery bypassed the airway and produced productive infection of kidney, liver, spleen, heart and gastrointestinal tract. Priming by intranasal infection before an intravenous challenge reduced distal viral loads. Circulating interferon was detected only in animals with lung titres, whatever the route.
The arc runs from supplying interferon to discovering that the host already supplies it systemically and that this is what keeps the infection respiratory. Hoagland 2021 treats the interferon system as something to be added at the airway. Carrau 2023 shows that productive airway replication is itself the source of a systemic antiviral state, which reframes extrapulmonary interferon signalling as a protective output of the lung rather than as evidence of distal infection, and makes the heterogeneity of presentation a function of how fast and how strongly the airway engages.
Neither study establishes a molecular mechanism, and both are careful about it. Hoagland 2021 does not resolve whether the reduced neutrophil presence follows from lower viral load, from a direct effect of interferon on recruitment, or from both, and the disseminated viral RNA proposal is circumstantial, resting on discordance between subgenomic RNA detection and infectious particle recovery with neither transfer nor sensor recognition tested. In Carrau 2023 the circulating interferon is a bioassay reading Mx induction rather than a direct protein measurement, since hamster reagents were unavailable, and it does not separate type I from type III interferon. Ifna could not be assessed at all because of genome annotation. Dexamethasone is a broad suppressor of transcription and direct effects on distal organs cannot be excluded. The intravenous arm used a thousandfold higher dose than the intranasal route, so route and dose are not independent. Viremia was detectable only after amplification, so its magnitude and route are unquantified. Hoagland 2021 used young animals that clear the virus and survive, so neither lethal disease nor age is represented, and the interferon intervention was tested as intranasal delivery to a rodent airway with no human dosing implication. Extension of the Carrau 2023 model to severe human COVID-19 or to Long Covid is offered by the authors as speculation.
The premise of this theme comes from the imbalanced host response, where Blanco-Melo 2020 established the low interferon and high chemokine pattern and Nilsson-Payant 2021 located the inflammatory arm in NF-kappa B. The hamster system built here becomes the shared platform for most of the rest of the area. Post-acute sequelae uses it in Frere 2022 and Serafini 2023 to ask what persists after clearance, and the observation that distal tissues respond without productive infection is the direct antecedent of that work. Immunity, age and reinfection varies the host in the same model, with Oishi 2022 in Cell Reports finding the interferon-stimulated gene response poorly sustained in older animals and Oishi 2022 in the Journal of Virology finding a residual interferon-stimulated state after influenza that suppresses a later SARS-CoV-2 challenge, which is the same priming logic arriving from a different direction. Models for pandemic virology treats the hamster itself as the object of assessment.
In golden hamsters, productive SARS-CoV-2 replication in the airways generates circulating type I and III interferon that primes every organ against infection, and blunting or bypassing that airway response permits viremia and productive infection of liver, kidney, spleen and brain.
Longitudinal transcriptional and histological profiling of SARS-CoV-2 infected golden hamsters maps a wave of inflammation that reaches tissues with little or no productive replication, and shows that intranasal type I interferon given before or after challenge lowers viral load and disease burden.